14 June 2019
Visiongain has launched a new pharma report Generic Drugs Market Forecast: Growth in Leading Regional and National Markets – North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America, US, Canada, Germany, France, UK, Italy, Spain, India, China, Australia, South Korea, Japan, South Africa, Saudi Arabia, U.A.E, Brazil, Argentina, Mexico, Teva, Novartis, Mylan, Pfizer, Abbott, Sun Pharma, Aspen, Fresenius Kabi, Sanofi, Dr. Reddy’s Laboratories Limited, Apotex.
Generic drugs play a major role in the pharmaceutical industry of most nations. This rings true for countries both in developed and developing economic regions. Generic drugs typically account for over 50-80% of pharmaceutical sales by volume and 10-20% of sales by value. Traditional pharmaceutical companies in the past have viewed generics as ways of diversifying their business. Over the last two decades, sales of these products in emerging markets in particular have provided major growth opportunities for traditional pharma companies.
The lead analyst of the report commented "Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area. At the same time, successful generic companies will try to innovate, pursuing more research-based pipeline candidates releasing patented drugs as well as high-value generics and biosimilars. A note of caution has to be sounded, however, in that we note that generic drug manufacturers must continuously revise their business models in an attempt to outsmart market challenges. New strategic decisions will have to be made to define their future path. This may include steps such as merging for scale, complementing the generic portfolio with a branded portfolio, or adding new offerings and services in order to provide new revenue streams."
Leading companies featured in the report include Abbott, Apotex, Aspen, Dr. Reddy’s Laboratories Limited, Fresenius Kabi, Mylan, Novartis, Pfizer, Sanofi, Sun Pharma, Teva and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.
11 October 2021
High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.
07 October 2021
Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.
06 October 2021
Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market